Benitec Biopharma Inc. (NASDAQ:BNTC) Director Buys $403,200.00 in Stock

Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L bought 42,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $9.60 per share, with a total value of $403,200.00. Following the completion of the transaction, the director now directly owns 7,957,365 shares of the company’s stock, valued at $76,390,704. This trade represents a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Benitec Biopharma Stock Performance

Benitec Biopharma stock opened at $11.23 on Friday. The business has a 50 day simple moving average of $10.32 and a 200-day simple moving average of $9.17. Benitec Biopharma Inc. has a 12 month low of $2.69 and a 12 month high of $12.89.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BNTC. Oppenheimer started coverage on Benitec Biopharma in a report on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 price objective for the company. Guggenheim reissued a “buy” rating and issued a $17.00 price target on shares of Benitec Biopharma in a report on Tuesday, December 3rd. JMP Securities raised their price objective on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Monday, October 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Benitec Biopharma has a consensus rating of “Buy” and an average target price of $22.60.

Institutional Investors Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,884 shares during the period. Acuta Capital Partners LLC purchased a new position in Benitec Biopharma in the 3rd quarter valued at about $274,000. Simplify Asset Management Inc. acquired a new stake in Benitec Biopharma in the 2nd quarter worth about $358,000. Geode Capital Management LLC increased its stake in Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after buying an additional 20,012 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Benitec Biopharma by 35.5% during the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after acquiring an additional 64,092 shares during the last quarter. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.